Monica M. Reinholz
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester
MN 55906
USA
Name/email consistency: high
- A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Reinholz, M.M., Zinnen, S.P., Dueck, A.C., Dingli, D., Reinholz, G.G., Jonart, L.A., Kitzmann, K.A., Bruzek, A.K., Negron, V., Abdalla, A.K., Arendt, B.K., Croatt, A.J., Sanchez-Perez, L., Sebesta, D.P., Lönnberg, H., Yoneda, T., Nath, K.A., Jelinek, D.F., Russell, S.J., Ingle, J.N., Spelsberg, T.C., Dixon, H.B., Karpeisky, A., Lingle, W.L. Bone (2010)
- Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform. Reinholz, M.M., Eckel-Passow, J.E., Anderson, S.K., Asmann, Y.W., Zschunke, M.A., Oberg, A.L., McCullough, A.E., Dueck, A.C., Chen, B., April, C.S., Wickham-Garcia, E., Jenkins, R.B., Cunningham, J.M., Jen, J., Perez, E.A., Fan, J.B., Lingle, W.L. BMC. Med. Genomics (2010)
- Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Reinholz, M.M., Nibbe, A., Jonart, L.M., Kitzmann, K., Suman, V.J., Ingle, J.N., Houghton, R., Zehentner, B., Roche, P.C., Lingle, W.L. Clin. Cancer Res. (2005)
- Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Reinholz, M.M., An, M.W., Johnsen, S.A., Subramaniam, M., Suman, V.J., Ingle, J.N., Roche, P.C., Spelsberg, T.C. Breast Cancer Res. Treat. (2004)
